Daniela Rottoli

List of Publications by Citations

Source: https://exaly.com/author-pdf/10115659/daniela-rottoli-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,840 30 41 39 h-index g-index citations papers 8.4 4,194 41 4.41 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
39	Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1794-804	12.7	615
38	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 524-30	15.9	374
37	Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. <i>Stem Cells</i> , 2008 , 26, 2075-82	5.8	326
36	Insulin-like growth factor-1 sustains stem cell mediated renal repair. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 2921-8	12.7	264
35	Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. Journal of Clinical Investigation, 2015 , 125, 715-26	15.9	244
34	Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. <i>Journal of Immunology</i> , 2011 , 187, 172-80	5.3	186
33	Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1816-24	12.7	160
32	How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2898-908	12.7	131
31	Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. <i>American Journal of Pathology</i> , 2002 , 161, 2179-93	5.8	116
30	Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2436-46	12.7	105
29	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, F1448-56	4.3	97
28	Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002 , 61, 2066-77	9.9	97
27	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002 , 61, 1635-45	9.9	88
26	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , 2017 , 8, 983	17.4	85
25	Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 804-13	12.7	84
24	Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 1624-32	12.7	73
23	Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. <i>PLoS ONE</i> , 2013 , 8, e70775	3.7	68

(2017-2006)

22	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , 2006 , 70, 97-103	9.9	66
21	Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. <i>American Journal of Pathology</i> , 2007 , 170, 1165-77	5.8	61
20	Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1158-67	12.7	54
19	Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, F1114-23	4.3	51
18	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009 , 76, 960-7	9.9	46
17	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001 , 60, 653-63	9.9	45
16	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , 2017 , 60, 1114-1125	10.3	44
15	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004 , 66, 1959-65	9.9	43
14	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1629-37		42
13	Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1786-98	12.7	39
12	Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. <i>Nephron Experimental Nephrology</i> , 2006 , 104, e158-68		36
11	Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. <i>Nephron</i> , 2015 , 129, 52-61	3.3	35
10	Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. <i>Journal of Immunology</i> , 2008 , 181, 1460-9	5.3	35
9	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016 , 132, 59-69	3.3	30
8	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic hephropathy. <i>Kidney International</i> , 2019 , 96, 906-917	9.9	23
7	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018 , 9, 220	8.3	19
6	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. <i>EBioMedicine</i> , 2015 , 2, 456-66	8.8	17
5	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. <i>American Journal of Pathology</i> , 2017 , 187, 2441-2450	5.8	16

4	COVID-19 Attacks the Kidney: Ultrastructural Evidence for the Presence of Virus in the Glomerular Epithelium. <i>Nephron</i> , 2020 , 144, 341-342	3.3	14
3	Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. <i>Journal of Hypertension</i> , 2018 , 36, 1129-1146	1.9	5
2	Histological Examination of the Diabetic Kidney. Methods in Molecular Biology, 2020, 2067, 63-87	1.4	3
1	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021 , 145, 428-444	3.3	2